Bictegravir
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Bictegravir
- Pharmacist Assessment Report
- Bictegravir: HIV-1 integrase strand transfer inhibitor → simian immunodeficiency virus infection
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bictegravir: HIV-1 integrase strand transfer inhibitor → simian immunodeficiency virus infection
One-Sentence Summary
Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) supplied in Australia as a fixed-dose tablet with emtricitabine and tenofovir alafenamide. The TxGNN model predicts it may be effective for simian immunodeficiency virus infection, a non-human animal disease model. Support is limited to 0 clinical trials and 3 publications (in vitro, structural review and humanised mouse model), so this is a research question rather than a treatment proposal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | simian immunodeficiency virus infection |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, bictegravir is an INSTI: it blocks the integrase enzyme that inserts viral DNA into the host genome.
SIV and HIV-1 are closely related lentiviruses, and their integrases are structurally similar. The SIV intasome has been used as a structural model for how INSTIs bind. Bictegravir therefore plausibly acts on SIV integrase by the same mechanism. A 2017 in vitro study reported activity against INSTI-resistant SIVmac239 variants.
An important caveat: SIV infection is an infection of non-human primates and serves as a translational research model for HIV. It is not a human therapeutic indication. The value of this prediction lies in preclinical research, not in a new clinical use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28923862 | 2017 | In vitro study | Antimicrob Agents Chemother | Bictegravir and cabotegravir showed antiviral activity against INSTI-resistant SIVmac239 and HIV-1 variants |
| 32506843 | 2021 | Review (structural biology) | FEBS J | HIV/SIV intasome structures explain INSTI binding and resistance; dolutegravir and bictegravir have high resistance barriers |
| 39559349 | 2024 | Preclinical animal model | Front Immunol | Humanised mouse model proposed for testing antiviral strategies against both SIV and HIV |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11649D | Biktarvy | Tablet containing bictegravir 50 mg with emtricitabine 200 mg with tenofovir alafenamide 25 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 81 interactions were identified in the data compiled for this report. Major-level examples include polyvalent cation products that can reduce absorption: aluminium hydroxide, magaldrate, magnesium carbonate/chloride/citrate, calcium salts (acetate, carbonate, citrate, gluconate, lactate, phosphate), iron, kaolin and attapulgite. Moderate-level examples include aprepitant, clarithromycin, dexamethasone, eliglustat and glycerol phenylbutyrate.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support is preclinical and indirect, and SIV infection is an animal research model rather than a human indication. There are no clinical trials, so no repurposing action in humans is justified at present.
To proceed, the following is needed:
- Direct preclinical data on bictegravir in SIV animal models (for example, humanised mouse or non-human primate studies)
- Detailed mechanism of action data
- Warnings and contraindications from the TGA Product Information
- A defined research purpose (for example, use as a translational model for HIV cure studies) before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.